Mesangial pathology in glomerular disease: Targets for therapeutic intervention

Advanced Drug Delivery Reviews

Volumn 62, Issue 14, 2010, Pages 1337-1343

  Scindia, Yogesh M ^a   Deshmukh, Umesh S ^a   Bagavant, Harini ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Gene therapy; Glomerular targeting; Glomerulonephritis; Immunoliposomes; Mesangial cells; Mouse models

Indexed keywords

GLOMERULAR TARGETING; GLOMERULONEPHRITIS; IMMUNOLIPOSOMES; MESANGIAL CELLS; MOUSE MODELS;

DISEASES; DRUG DELIVERY; ENDOTHELIAL CELLS; GENETIC ENGINEERING; PATHOLOGY;

GENE THERAPY;

3,5 DIPENTADECYLOBENZAMIDINE; CYCLIN DEPENDENT KINASE 2; CYCLINE; DEHYDROXYMETHYL EPOXYQUINOMICIN; IMATINIB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOSOME; MACROGOL; NANOCARRIER; PLATELET DERIVED GROWTH FACTOR; PREDNISONE PHOSPHATE; PROTEIN INHIBITOR; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA ANTIBODY; UNCLASSIFIED DRUG; VARDENAFIL;

APOPTOSIS; CANCER THERAPY; CELL PROLIFERATION; CELL SURVIVAL; CREATININE CLEARANCE; CYTOARCHITECTURE; DIABETES MELLITUS; DRUG DOSAGE FORM COMPARISON; DRUG TARGETING; EXPERIMENTAL ANIMAL; EXPERIMENTAL MOUSE; GENE THERAPY; GENE TRANSFER; GENETIC SUSCEPTIBILITY; GLOMERULONEPHRITIS; GLOMERULOPATHY; GLOMERULUS FILTRATION; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY DISEASE; LIPOSOMAL DELIVERY; MESANGIUM CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TRANSCRIPTION REGULATION;

ANIMALS; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; GLOMERULAR MESANGIUM; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; MESANGIAL CELLS; MICE; MOLECULAR TARGETED THERAPY; RATS;

EID: 78649447461     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.08.011     Document Type: Review

References (68)

1. Smith A., Hendry B. The Regulation of Mesangial Cell Proliferation. Nephron Exp. Nephrol. 2008, 108:74-79.
2. Schlondorff D., Banas B. The Mesangial Cell Revisited: No Cell Is an Island. J. Am. Soc. Nephrol. 2009, 20:1179-1187.
3. Olivetti G., Anversa P., Rigamonti W., Vitali-Mazza L., Loud A.V. Morphometry of the renal corpuscle during normal postnatal growth and compensatory hypertrophy: a light microscope study. J. Cell Biol. 1977, 75:573-585.
4. Stockand J.D., Sansom S.C. Glomerular mesangial cells: Electrophysiology and regulation of contraction. Physiol. Rev. 1998, 78:723-744.
5. Sraer J.D., Adida C., Peraldi M.N., Rondeau E., Kanfer A. Species-specific properties of the glomerular mesangium. J. Am. Soc. Nephrol. 1993, 3:1342-1350.
6. Lee H.S., Song C.Y. Differential role of mesangial cells and podocytes in TGF-beta-induced mesangial matrix synthesis in chronic glomerular disease. Histol. Histopathol. 2009, 24:901-908.
7. Picken M.M. The role of mesangial homeostasis in glomerular injury progression: hope for mesangial sclerosis reversal. Kidney Int. 2009, 75:574-576.
8. Qian Y., Feldman E., Pennathur S., Kretzler M., Brosius F.C. From fibrosis to sclerosis: mechanisms of glomerulosclerosis in diabetic nephropathy. Diabetes 2008, 57:1439-1445.
9. Wada T., Matsushima K., Kaneko S. The role of chemokines in glomerulonephritis. Front. Biosci. 2008, 1:3966-3974.
10. Cameron J.S. Lupus nephritis. J. Am. Soc. Nephrol. 1999, 10:413-424.
11. Tumlin J.A., Madaio M.P., Hennigar R. Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options. Clin. J. Am. Soc. Nephrol. 2007, 2:1054-1061.
12. Ronco P., Ardaillou R., Baud L., Friedlander G. Biology of renal cells in culture. Brenner and Rector's The Kidney 2004, 105-198. Elsevier Inc., Philadelphia. B.M. Brenner (Ed.).
13. Nangaku M., Couser W.G. Mechanisms of immune-deposit formation and the mediation of immune renal injury. Clin. Exp. Nephrol. 2005, 9:183-191.
14. Lema P.G., Maier H., Nieto E., Vielhauer V., Luckow B., Mampaso F., Schlöndorff D. Chemokine expression precedes inflammatory cell infiltration and chemokine receptor and cytokine expression during the initiation of murine lupus nephritis. J. Am. Soc. Nephrol. 2001, 12:1369-1382.
15. Bagavant H., Deshmukh U.S., Wang H., Ly T., Fu S.M. Role for nephritogenic T cells in lupus glomerulonephritis: progression to renal failure is accompanied by T cell activation and expansion in regional lymph nodes. J. Immunol. 2006, 177:8258-8265.
16. Roberts A.B., McCune B.K., Sporn M.B. TGF-beta: regulation of extracellular matrix. Kidney Int. 1992, 41:557-559.
17. Border W.A., Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J. Med. 1994, 331:1286-1292.
18. Ian S.D., Roberts H., Cook T., Troyanov S., Alpers C.E., Amore A., Barratt J., Berthoux F., Bonsib S., Bruijn J.A., Cattran D.C., Coppo R., D'Agati V., D'Amico G., Emancipator S., Emma F., Feehally J., Ferrario F., Fervenza F.C., Florquin S., Fogo A., Geddes C.C., Groene H., Haas M., Herzenberg A.M., Hill P.A., Hogg R.J., Hsu S.I., Jennette J.C., Joh K., Julian B.A., Kawamura T., Lai F.M., Li L.S., Li P.K.T., Liu Z., Mackinnon B., Mezzano S., Schena F., Tomino Y., Walker P.D., Wang H., Weening J.J., Yoshikawa N., Zhang H. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009, 76:546-556.
19. Coppo R., Amore A. Aberrant glycosylation in IgA nephropathy (IgAN). Kidney Int. 2004, 65:1544-1547.
20. Tam K.Y., Leung J.C., Chan L.Y., Lam M.F., Tang S.C., Lai K.N. Macromolecular IgA1 taken from patients with familial IgA nephropathy or their asymptomatic relatives have higher reactivity to mesangial cells in vitro. Kidney Int. 2009, 75:1330-1339.
21. Coppo R., Fonsato V., Balegno S., Ricotti E., Loiacono E., Camilla R., Peruzzi L., Amore A., Bussolati B., Camussi G. Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes. Kidney Int. 2010, 77:417-427.
22. Steffes M.W., Osterby R., Chavers B., Mauer S.M. Mesangial expansion as a central mechanism for loss of kidney function in diabetic patients. Diabetes 1989, 38:1077-1081.
23. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-De La Cruz M.C., Hong S.W., Isono M., Chen S., McGowan T.A., Sharma K. Long term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal anti-transforming growth factor-ß antibody in db/db diabetic mice. Proc. Natl Acad. Sci. USA 2000, 97:8015-8020.
24. Thrailkill K.M., Clay B.R., Bunn R., Fowlkes J.L. Matrix metalloproteinases: their potential role in the pathogenesis of diabetic nephropathy. Endocr. 2009, 35:1-10.
25. Turbat-Herrera E.A., Isaac J., Sanders P.W., Truong L.D., Herrera G.A. Integrated expression of glomerular extracellular matrix proteins and beta 1 integrins in monoclonal light chain-related renal diseases. Mod. Pathol. 1997, 10:485-495.
26. Bagchus W.M., Hoedemaeker P.J., Rozing J., Bakker W.W. Glomerulonephritis induced by monoclonal anti-Thy 1.1 antibodies. A sequential histological and ultrastructural study in the rat. Lab. Invest. 1986, 55:680-687.
27. Christensen M., Su A.W., Snyder R.W., Greco A., Lipschutz J.H., Madaio M.P. Simvastatin protection against acute immune-mediated glomerulonephritis in mice. Kidney Int. 2006, 69:457-463.
28. Carl M.Y., Akagi S., Weidner S., Isaka Y., Imai E., Rupprecht H.D. Specific inhibition of Egr-1 prevents mesangial cell hypercellularity in experimental nephritis. Kidney Int. 2003, 63:1302-1312.
29. Zoja C., Corna D., Rottoli D., Zanchi C., Abbate M., Remuzz G. Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney Int. 2006, 70:97-103.
30. Tesch G.H., Allen T.J. Rodent models of streptozotocin- induced diabetic nephropathy. Nephrology 2007, 12:261-266.
31. Fu Y., Du Y., Mohan C. Experimental anti-GBM disease as a tool for studying spontaneous lupus nephritis. Clin. Immunol. 2007, 124:109-118.
32. Bagavant H., Deshmukh U.S., Gaskin F., Fu S.M. Lupus glomerulonephritis revisited 2004: autoimmunity and end-organ damage. Scand. J. Immunol. 2004, 60:52-63.
33. D'Agord S.B., Lacchini S., Bertoluci M.C., Irigoyen M.C., Machado U.F., Schmid H. Increased renal GLUT1 abundance and urinary TGF-beta 1 in streptozotocin-induced diabetic rats: implications for the development of nephropathy complicating diabetes. Horm. Metab. Res. 2001, 33:664-669.
34. Massy Z.A., Guijarro C., ODonnell M.P., Kim Y.K., Kashtan C.E., Egido J., Kasiske B.L., Keane W.F. The central role of nuclear factor ßB in mesangial cell activation. Kidney Int. 1999, 56(Suppl 71):76-79.
35. Duque H.N., Gómez-Guerrero C., Egido J. Interaction of IgA with Fcγ receptors of human mesangial cells activates transcription factor nuclear factor-ßB and induces expression and synthesis of monocyte chemoattractant protein-1, IL-8 and IFN-inducible protein 10. J. Immunol. 1997, 159:3474-3482.
36. Bamborough P., Callahan J.F., Christopher J.A., Kerns J.K., Miller J., Liddle D.D., Morse M.A., Rumsey W.L., Williamson R. Progress Towards the Development of Anti-Inflammatory Inhibitors of IKKβ. Curr. Top. Med. Chem. 2009, 9:623-639.
37. Kosaka T., Miyajima A., Kikuchi E., Horiguchi Y., Umezawa K., Ohigashi T., Nakashima J., Asano T., Oya M. The novel NF-kappaB activation inhibitor dehydroxymethyl-epoxyquinomicin suppresses anti-Thy1.1-induced glomerulonephritis in rats. Nephron Exp. Nephrol. 2008, 110:17-24.
38. Auphan N., DiDonato J.A., Rosette C., Helmberg A., Karin M. Immunosuppression by glucocorticoids: inhibition of NF-Κ B activity through induction of IΚB synthesis. Science 1995, 270:286-290.
39. Shultz P.J., DiCorleto P.E., Silver B.J., Abboud H.E. Mesangial cells express PDGF mRNAs and proliferate in response to PDGF. Am. J. Physiol. 1988, 255:674-684.
40. Doi T., Vlassarat H., Kirsteint M., Yamadat Y., Striker G.E., Striker L.J. Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor. Proc. Natl Acad. Sci. 1992, 89:2873-2877.
41. Gilbert R.E., Kelly D.J., Mckay T., Chadban S., Hill P.A., Cooper M.E., Atkins R.C., Nikolic-Paterson D.J. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int. 2001, 59:1324-1332.
42. Bagavant H., Fu S.M. Pathogenesis of kidney disease in systemic lupus erythematosus. Curr. Opin. Rheumatol. 2009, 21:489-494.
43. Fukasawa H., Yamamoto T., Suzuki H., Togawa A., Ohashi N., Fujigaki Y., Uchida C., Aoki M., Hosono M., Kitagawa M., Hishida A. Treatment with anti-TGF-β antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-β signaling. Kidney Int. 2004, 65:63-74.
44. Hohenstein B., Daniel C., Wittmann S., Hugo C. PDE-5 inhibition impedes TSP-1 expression, TGF-β activation and matrix accumulation in experimental glomerulonephritis. Nephrol. Dial. Transplant. 2008, 23:3427-3436.
45. Xie C., Zhou X.J., Liu X., Mohan C. Enhanced susceptibility to end-organ disease in the lupus-facilitating NZW mouse strain. Arthritis Rheum. 2003, 48:1080-1092.
46. Bagavant H., Thompson C., Ohno K., Setiady Y., Tung K.S. Differential effect of neonatal thymectomy on systemic and organ-specific autoimmune disease. Int. Immunol. 2002, 14:1397-1406.
47. Ge Y., Jiang C., Morris A., Gaskin F., Sung S.-S., Bagavant H., Fu S.M. Acute Glomerulonephritis without Progression to Chronic Glomerulonephritis, Renal Failure and Early Mortality in Female Mice of Congenic Strain NZM2328.Lc1R27. Arthritis Rheum. 2008, 58:S441.
48. Xie C., Sharma R., Wang H., Zhou X.J., Mohan C. Strain distribution pattern of susceptibility to immune-mediated nephritis. J. Immunol. 2004, 172:5047-5055.
49. Kaneda Y., Saeki Y., Morishita R. Gene therapy using HVJ liposomes: the best of both worlds. Mol. Med. Today 1999, 5:298-303.
50. Isaka Y. Gene therapy targeting kidney diseases: routes and vehicles. Clin. Exp. Nephrol. 2006, 10:229-235.
51. Jeong H.S., Park K.K., Park K.K., Kim S.P., Choi I.J., Lee I.K., Kim H.C. Effect of antisense TGF-beta1 oligodeoxynucleotides in streptozotocin induced diabetic rat kidney. J. Korean Med. Sci. 2004, 19:374-383.
52. Tomita N., Higaki J., Morishita R., Kato K., Mikami H., Kaneda Y., Ogihara T. Direct in vivo gene introduction into rat kidney. Biochem. Biophys. Res. Commun. 1992, 186:129-134.
53. Tomita N., Kim J.Y., Gibbons G.H., Zhang L., Kaneda Y., Stahl R.A., Ogborn M., Venderville B., Morishita R., Baran D., Dzau V.J. Gene therapy with an E2F transcription factor decoy inhibits cell cycle progression in rat anti-Thy 1 glomerulonephritis. Int. J. Mol. Med. 2004, 13:629-636.
54. Kang J.H., Chae Y.M., Park K.K., Kim C.H., Lee I.S., Chang Y.C. Suppression of mesangial cell proliferation and extracellular matrix production in streptozotocin-induced diabetic rats by Sp1 decoy oligodeoxynucleotide in vitro and in vivo. J. Cell. Biochem. 2008, 103:663-674.
55. Ahn J.D., Morishita R., Kaneda Y., Kim H.J., Kim Y.D., Lee H.J., Lee K.U., Park J.Y., Kim Y.H., Park K.K., Chang Y.C., Yoon K.H., Kwon H.S., Park K.G., Lee I.K. Transcription factor decoy for AP-1 reduces mesangial cell proliferation and extracellular matrix production in vitro and in vivo. Gene Ther. 2004, 11:916-923.
56. Manil L., Davin J.C., Duchenne C., Kubiak C., Foidart J., Couvreur P., Mahieu P. Uptake of nanoparticles by rat glomerular mesangial cells in vivo and in vitro. Pharm. Res. 1994, 11:1160-1165.
57. Klibanov L., Maruyama K., Torchilin V.P., Huang L. Amphipatic polyethyleneglycols effectively prolong the circulation time of liposomes. FEBS Lett. 1990, 268:235-238.
58. Harigai T., Kondo M., Isozaki M., Kasukawa H., Hagiwara H., Uchiyama H., Kimura J. Preferential binding of polyethylene glycol-coated liposomes containing a novel cationic lipid, TRX-20, to human subendthelial cells via chondroitin sulfate. Pharm. Res. 2001, 18:1284-1290.
59. Morimoto K., Kondo M., Kawahara K., Ushijima H., Tomino Y., Miyajima M., Kimura J. Advances in targeting drug delivery to glomerular mesangial cells by long circulating cationic liposomes for the treatment of glomerulonephritis. Pharma Res. 2007, 24:946-954.
60. Shimizu H., Hori Y., Kaname S., Yamada K., Nishiyama N., Matsumoto S., Miyata K., Oba M., Yamada A., Kataoka K., Fujita T. siRNA-based therapy ameliorates glomerulonephritis. J. Am. Soc. Nephrol. 2010, 21:622-633.
61. Tomita N., Morishita R., Yamamoto K., Higaki J., Dzau V.J., Ogihara T., Kaneda Y. Targeted gene therapy for rat glomerulonephritis using HVJ-immunoliposomes. J. Gene Med. 2002, 4:527-535.
62. Tuffin G., Waelti E., Huwyler J., Hammer C., Marti H. Immunoliposome Targeting to Mesangial Cells: A Promising Strategy for Specific Drug Delivery to the Kidney. J. Am. Soc. Nephrol. 2005, 16:3295-3305.
63. Tuffin G., Huwyler J., Waelti E., Hammer C., Mart H. Drug targeting using OX7-immunoliposomes: Correlation between Thy1.1 antigen expression and tissue distribution in the rat. J. Drug Target. 2008, 16:156-166.
64. Scindia Y., Deshmukh U., Thimmalapura P.R., Bagavant H. Anti-α8 integrin immunoliposomes in glomeruli of lupus-susceptible mice a novel system for delivery of therapeutic agents to the renal glomerulus in systemic lupus Erythematosus. Arthritis Rheum. 2008, 58:3884-3891.
65. Hartner A., Schocklmann H., Prols F., Muller U., Sterzel R.B. Alpha 8 integrin in glomerular mesangial cells and in experimental glomerulonephritis. Kidney Int. 1999, 56:1468-1480.
66. Schnapp L.M., Breuss J.M., Ramos D.M., Sheppard D., Pytela R. Sequence and tissue distribution of the human integrin alpha subunit: beta1-associated alpha subunit expressed in smooth muscle cells. J. Cell Sci. 1995, 108:537-544.
67. Deshmukh U.S., Nandula S.R., Thimmalapura P.R., Scindia Y.M., Bagavant H. Activation of innate immune responses through Toll-like receptor 3 causes a rapid loss of salivary gland function. J. Oral Pathol. Med. 2009, 38:42-47.
68. Liu K., Li Q.Z., Delgado-Vega A.M., Abelson A.K., Sánchez E., Kelly J.A., Li L., Liu Y., Zhou J., Yan M., Ye Q., Liu S., Xie C., Zhou X.J., Chung S.A., Pons-Estel B., Witte T., de Ramón E., Bae S.C., Barizzone N., Sebastiani G.D., Merrill J.T., Gregersen P.K., Gilkeson G.G., Kimberly R.P., Vyse T.J., Kim I., D'Alfonso S., Martin J., Harley J.B., Criswell L.A., Wakeland E.K., Alarcón-Riquelme M.E., Mohan C. Kallikrein genes are associated withlupus and glomerular basement membrane-specific antibody-induced nephritis in mice and humans. J. Clin. Invest. 2009, 119:911-923. Profile Study Group, Italian Collaborative GroupItalian Collaborative Group, German Collaborative GroupGerman Collaborative Group, Spanish Collaborative GroupSpanish Collaborative Group, Argentinian Collaborative GroupArgentinian Collaborative Group, SLEGEN ConsortiumSLEGEN Consortium.